Related Experiment Video
Updated: Apr 14, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients
Qing Zhang1, Lei Zhu2, Jie Zhang3
1Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China. qingzhang86@hotmail.com.
Background:
Although new individual treatments continue to reshape the landscape of clinical care in patients with lung cancer, most of the progress has been mainly of benefit to patients with lung adenocarcinomas rather than squamous cell lung carcinoma (SQCLC). Our study aimed to determine whether the epidermal growth factor receptor (EGFR) gene mutation is present in pure SQCLC. We further determined the mutation frequency and the clinical and pathological features of groups that are in high risk for EGFR mutation.
Methods:
A total of 185 Chinese patient specimens diagnosed as SQCLC in the Shanghai Chest Hospital at the Shanghai Jiao Tong University were selected for this study. Hematoxylin-eosin stained slides for all cases were reviewed and evaluated by immunohistochemical analysis with the aim of selecting samples with pure SQCLC. After screening, 22 cases were eliminated and 163 pure SQCLC cases remained. Amplification Refractory Mutation System was used to detect the EGFR gene mutation status in the 163 SQCLC specimens.
Results:
A total of 28 cases with EGFR mutation were detected among the 163 specimens. The EGFR mutation rate was 17.2% (28/163). Sex and smoking status were significantly associated with the status of EGFR gene mutation (P = 0.022 and P = 0.049, respectively). Age and degree of differentiation were not significantly correlated to EGFR mutation (P = 0.730 and P = 0.651, respectively).
Conclusions:
EGFR mutations are present in pure SQCLC, which are more frequently detected in females and nonsmoker patients. Our results indicate the importance for all patients with SQCLC to have EGFR mutation status examined. These patients with activating EGFR mutation could accept tyrosine kinase inhibitors (TKIs) treatment.
Insights
Epidermal growth factor receptor (EGFR) mutations are present in squamous cell lung carcinoma (SQCLC), particularly in females and non-smokers. Testing for EGFR mutations in SQCLC patients is crucial for guiding treatment with tyrosine kinase inhibitors (TKIs).
Area of Science:
- Oncology
- Genetics
- Pulmonology
Background:
- Lung cancer treatment advances primarily benefit adenocarcinoma, not squamous cell lung carcinoma (SQCLC).
- Investigating epidermal growth factor receptor (EGFR) gene mutations in pure SQCLC is essential.
- Understanding EGFR mutation frequency and associated clinical features in SQCLC is critical.
Purpose of the Study:
- To determine the presence and frequency of EGFR gene mutations in pure SQCLC.
- To identify clinical and pathological features associated with EGFR mutations in SQCLC.
- To evaluate the potential for targeted therapies in SQCLC based on EGFR mutation status.
Main Methods:
- Analysis of 163 pure SQCLC patient specimens from Shanghai Chest Hospital.
- Immunohistochemical analysis to confirm pure SQCLC histology.
- Amplification Refractory Mutation System (ARMS) to detect EGFR gene mutations.
Main Results:
- EGFR mutations were detected in 17.2% (28/163) of SQCLC specimens.
- EGFR mutation status was significantly associated with female sex and non-smoking status.
- No significant correlation was found between EGFR mutation and age or degree of differentiation.
Conclusions:
- EGFR mutations are present in a subset of pure SQCLC patients.
- EGFR mutations are more common in females and non-smokers with SQCLC.
- EGFR mutation testing is recommended for all SQCLC patients to identify candidates for tyrosine kinase inhibitor (TKI) therapy.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...